Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 81.82 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $1.708 million which beat the analyst consensus estimate of $500.000 thousand by 241.60 percent. This is a 893.02 percent increase over sales of $172.000 thousand the same period last year.